Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
CCTG is pleased to announce that Dr. Martin Smoragiewicz has joined the group as a Senior Investigator. Dr. Smoragiewicz is a medical oncologist who completed his undergraduate BSc and MD.CM at McGill University, and internal medicine and medical oncology training in British Columbia. He has completed a fellowship in early phase clinical trials at the University of Cambridge, focusing on immune approaches in pancreatic cancer as part of a PhD program. Dr. Smoragiewicz will be working with Lesley Seymour in the IND program.
The Quality of Life committee is currently seeking 2-3 individuals with enthusiastic interest in the measurement of patient-reported outcomes in clinical trials.
CCTG network researchers have been recognized by Governor General Julie Payette who announced the Order of Canada appointments on Friday, Dec. 29. Please join us in congratulating Dr. Pritchard, Dr. Gleave and Dr. Eisenhauer on this wonderful honour and for their outstanding contributions to cancer clinical trial research in Canada.
Links to online citations of previously published CCTG studies are listed here.
IND.234 - Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol has been centrally activated with participation limited to invited centres.
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor. Position Title: Monitor/Auditor Position Number: 00125702 Employee Group: General Staff/Research - Office of Compliance and Oversight Salary Grade: 8 Terms: 35 hours/week
